All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The all Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the all Hub cannot guarantee the accuracy of translated content. The all and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer and supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View all content recommended for you
Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
Featured:
Ali BazarbachiDuring the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the ALL Hub spoke to Ali Bazarbachi, American University of Beirut, Beirut, LB. We asked, Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
Have you seen an improvement in OS for patients who relapse after HSCT over the past 20 years?
In this video, Bazarbachi discusses the long-term prognosis for adult patients with Philadelphia chromosome-positive ALL who have relapsed after allogeneic hematopoietic stem cell transplant (HSCT), with reference to the 900 patients on the EBMT registry with this ALL subtype.